As the drug discovery industry takes on the complex disease states that plague our world, the need for more relevant and timely answers from cell-based assays has become a major challenge.
List view / Grid view
21 March 2018 | By Ben Jackson (Associate Director - Marketing - Bioline)
Next generation sequencing (NGS) has transformed biological research, invigorating the field of genomics, and has increased understanding of our genetic basis.
19 March 2018 | By Mark Wigglesworth (Director High-Throughput Screening - AstraZeneca)
Efficient microplate readers play an important role in effective hit molecule discovery. Mark Wigglesworth, of AstraZeneca, explains what he looks for in this technology.
19 March 2018 | By Laurence Painell (VP Marketing - IDBS)
A look back, and forward, at the key trends within laboratory informatics.
High throughput flow cytometry for multifactorial evaluation of novel therapeutic candidates using an innovative in vitro immunooncology screening platform
19 March 2018 | By IntelliCyt Corporation
This recent webinar focused on the role of IntelliCyt’s iQue Screener PLUS platform as a high throughput suspension cell screening platform to facilitate simultaneous assessment of multiple parameters, while using minimal sample volumes.
19 March 2018 | By Anis H. Khimani (PerkinElmer)
Physiologically relevant screening models have become increasingly important in assay development and the screening of drug candidates.
19 March 2018 | By Drug Target Review
Declining R&D productivity is a key challenge in the pharmaceutical industry. To increase the success rate of candidate drugs entering the clinical phase, companies must address the early stages of drug discovery.
Predictiveness is one of the key factors for success in the drug discovery workflow. Many compounds fail at late stages due to lack of predictive data or the discovery of unwanted side effects.
14 March 2018 | By Drug Target Review
In this issue: how customised cell engineering advances immunotherapy, how insights into auto-immunity are providing new opportunities for immune-oncology, and advances in lab automation and robotics are accelerating the pace of antimicrobial therapy.
4 January 2018 | By Simon Pearce (Thermo Fisher Scientific)
From the early use of Hansch parameters and Topliss Trees to today’s computational structure–activity techniques, medicinal chemists have long sought to rationalise drug design to find the quickest and most resource-efficient route to market. But while modern strategies are more reliant on statistical algorithms and vast data libraries, these founding…
14 December 2017 | By Richard Goodwin
A new race is well underway involving big pharma and big data companies to see who can most effectively mine the new massive data using artificial intelligence (AI). The aim: reducing costs by using targeted in silico analysis, reducing in vitro and in vivo screening, and reviewing huge quantities of…
14 December 2017 | By Alicia Landeira, Javier Carabias, Jonatan García, Manuel Fuentes (Cancer Research Centre), Maria Gonzalez-Gonzalez, Paula Díez (Cancer Research Centre), Rafael Góngora, Rodrigo Garcia-Valiente
Proteogenomics is the systematic and comprehensive integration of proteomics with genomics and transcriptomics. Proteogenomics is opening new hallmarks in biomedical research. Recently, several studies have demonstrated the relevance of proteogenomics in cancer research. This article provides a brief review of the advantages of proteogenomics in precision medicine.